We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV<sup>+</sup> DLBCL-NOS: a Chinese cohort study.
- Authors
Xing, Tong-Yao; Duan, Zi-Wen; Wang, Wei-Ting; Du, Kai-Xin; Shen, Hao-Rui; Yin, Hua; Wu, Jia-Zhu; Li, Yue; Wang, Li; Li, Jian-Yong; Liang, Jin-Hua; Xu, Wei
- Abstract
EBV-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL-NOS), is an EBV-positive clonal B-cell lymphoid proliferation and circulating EBV-DNA is a great indicator for prognosis among EBV associated disease. In this retrospective study, we report 66 EBV+ DLBCL cases among 2137 DLBCL-NOS cases diagnosed from 2013 to 2021 (prevalence of 6.0%). After a median follow-up of 27 months, progression-free survival (PFS) and overall survival (OS) at 2 years were 39.5% ± 6.2% and 53.6% ± 6.4%, respectively. Multivariate analysis showed that only the biomarker of the positivity of post treatment EBV-DNA had a borderline correlation with shorter PFS and OS (PFS: P = 0.053; OS: P = 0.065). Patients were divided into three subgroups according to dynamic changes of EBV-DNA status: EBV-DNA persistently negative group, EBV-DNA persistently positive group, and EBV-DNA transformed from positive to negative group; among the three groups, patients of the persistently positive group had worst PFS and OS (P = 0.0527 and P = 0.0139, respectively). Decline in EBV copies correlated significantly with treatment response as well. In conclusion, circulating EBV-DNA level played a vital role in prognostic and monitoring marker for EBV+ DLBCL-NOS.
- Subjects
CIRCULATING tumor DNA; PROGNOSIS; DIFFUSE large B-cell lymphomas; EPSTEIN-Barr virus diseases; PROGRESSION-free survival; COHORT analysis
- Publication
Annals of Hematology, 2023, Vol 102, Issue 9, p2471
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-023-05260-z